A triple-receptor peptide that engages GLP-1, GIP, and glucagon pathways at once - the three core signals studied in glucose handling, appetite regulation, and lipid metabolism. The most receptor-diverse incretin analog in this catalog.
Compound characterisation data. For Research Use Only - Not for Human Consumption.
Mechanism of Action
GLP-3 RT engages all three receptors simultaneously in vitro. Each triggers a distinct, complementary pathway in preclinical models.
GLP-1 Receptor
Insulin secretion · Appetite signaling · Gastric emptying
0.04 nM
GIP Receptor
Adipocyte lipid metabolism · Insulin sensitization
0.06 nM
Glucagon Receptor
Hepatic glucose regulation · Thermogenesis · NASH
0.28 nM
Why the glucagon receptor changes everything
GCGR co-agonism engages hepatic and thermogenic pathways not activated by GLP-1R or GIPR alone. Preclinical NASH models have examined GCGR-associated hepatic fat changes and UCP-1 expression in brown adipose tissue. In vitro and preclinical observations only.
Triple-agonist signaling map
One 39-residue backbone engages all three receptors, then branches into three complementary metabolic axes.
Receptor EC50 from in vitro cAMP assays. Illustrative schematic - in vitro / preclinical observations, research use only.
Receptor Selectivity Profile
GLP-3 RT's balanced triple-receptor engagement vs GLP-2 TZ (dual) and GLP-1 S (mono). EC50 from in vitro cAMP assays.
Pharmacokinetic Profile
GLP-3 RT uses the same C18 fatty diacid albumin-binding strategy as GLP-1 S, with a ~144-hour modeled plasma half-life. Curve draws on scroll.
Compound Profile
Molecular and pharmacological specs from published preclinical literature and Eon Peptides batch records.
| Common Name | GLP-3 RT |
| Code | LY3437943 |
| Class | GLP-1 / GIP / Glucagon Triple Agonist |
| Structure | 39-amino acid acylated peptide |
| Mol. Weight | ~4.7 kDa |
| Half-Life | ~6 days (weekly dosing) |
| Acylation | C18 fatty diacid · albumin binding |
| Status | Investigational · not approved |
| Purity | ≥99% HPLC Verified |
| Form | Lyophilized powder · sealed vial |
| Regulatory | Research Use Only - Not for Human Use |
Receptor Binding Affinity
EC50 from in vitro cAMP assays. Lower = stronger binding.
Sub-nanomolar binding at all three receptors. GLP-1R and GIPR both below 0.1 nM - the balanced agonism profile reported in vitro. In vitro only [2].
Why the C18 acyl chain matters
The C18 fatty diacid modification enables albumin binding, extending half-life to ~6 days. Same strategy as GLP-1 S.